[1. N. Ayala-Fontanez, D. C. Soler and T. S. McCormick, Current knowledge on psoriasis and autoimmune diseases, Psoriasis (Auckl)6 (2016) 7–32; https://doi.org/10.2147/PTT.S6495010.2147/PTT.S64950568313029387591]Search in Google Scholar
[2. C. E. M. Griffiths, J. M. van der Walt, D. M. Ashcroft, C. Flohr, L. Naldi, T. Nijsten and M. Augustin, The global state of psoriasis disease epidemiology: A workshop report, Br. J. Dermatol.177 (2017) e4–e7; https://doi.org/10.1111/bjd.1561010.1111/bjd.15610560008228555722]Search in Google Scholar
[3. M. Kaštelan, Psoriasis, Reumatizam64 (2017) 31–36.]Search in Google Scholar
[4. D. A. Springate, R. Parisi, E. Kontopantelis, D. Reeves, C. E. M. Griffiths and D. M. Ashcroft, Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study, Br. J. Dermatol.176 (2017) 650–658; https://doi.org/10.1111/bjd.1502110.1111/bjd.15021536324127579733]Search in Google Scholar
[5. P. di Meglio, F. Villanova and F. O. Nestle, Psoriasis, Cold Spring Harb. Perspect. Med.4 (2014) a015354; https://doi.org/10.1101/cshperspect.a01535410.1101/cshperspect.a015354410958025085957]Search in Google Scholar
[6. M. A. Lowes, M. Suarez-Farinas and J. G. Krueger, Immunology of psoriasis, Ann. Rev. Immunol.32 (2014) 227–255; https://doi.org/10.1146/annurev-immunol-032713-12022510.1146/annurev-immunol-032713-120225422924724655295]Search in Google Scholar
[7. J. Takeshita, S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie, A. S. Van Voorhees and J. M. Gefland, Psoriasis and comorbid diseases. Part I. Epidemiology, J. Am. Acad. Dermatol.76 (2017) 377–390; https://doi.org/10.1016/j.jaad.2016.07.06410.1016/j.jaad.2016.07.064573165028212759]Search in Google Scholar
[8. E. Dauden, S. Castaneda, C. Suarez, J. Garcia Campayo, A. J. Blasco, M. D. Aguilar, C. Ferrandiz, L. Puig and J. L. Sanchez-Carazo, Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis, J. Eur. Acad. Dermatol. Venereol.27 (2013) 1387–1404; https://doi.org/10.1111/jdv.1202410.1111/jdv.1202423134338]Search in Google Scholar
[9. F. O. Nestle, D. H. Kaplan and J. Barker, Psoriasis, N. Eng. J. Med.361 (2009) 496–509; https://doi.org/10.1056/NEJMra080459510.1056/NEJMra080459519641206]Search in Google Scholar
[10. Global report on psoriasis, World Health Organization 2016. www.who.int]Search in Google Scholar
[11. M. Meštrović, Suvremene spoznaje o etiopatogenezi psorijaze, Sveučilište u Zagrebu, Zagreb 2016.]Search in Google Scholar
[12. M. Haroon, P. Gallagher and O. FitzGerald, Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis, Ann. Rheum. Dis.74 (2015) 1045–1050; https://doi.org/10.1136/annrheumdis-2013-20485810.1136/annrheumdis-2013-20485824525911]Search in Google Scholar
[13. C. Conrad and M. Gilliet, Psoriasis: from pathogenesis to targeted therapies, Clin. Rev. Allergy Immunol.54 (2018) 102–113; https://doi.org/10.1007/s12016-018-8668-110.1007/s12016-018-8668-129349534]Search in Google Scholar
[14. W-H. Boehncke and N. C. Brembilla, Unmet needs in the field of psoriasis: pathogenesis and treatment, Clin. Rev. Allergy Immunol.55 (2018) 295–311; https://doi.org/10.1007/s12016-017-8634-310.1007/s12016-017-8634-328780731]Search in Google Scholar
[15. S. R. Feldman, Treatment of psoriasis in adults; https://www.uptodate.com/contents/treatment-ofpsoriasis-in-adults]Search in Google Scholar
[16. E. Christophers and U. Mrowietz, Psoriasis, in Braun-Falco’s Dermatology (Eds. Burgdorf, Plewig, Wolf, Landthaller), 3rd ed., Springer, Berlin 2009, pp. 506–526.10.1007/978-3-540-29316-3_36]Search in Google Scholar
[17. E. C. Siegfried, J. C. Jaworski and A. A. Herbert, Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice, Am. J. Clin. Dermatol.14 (2013) 163–178; https://doi.org/10.1007/s40257-013-0020-110.1007/s40257-013-0020-1366949923703374]Search in Google Scholar
[18. K. Kragballe and P. C. van de Kerkhof, Consistency of data in six phase III clinical studies of a two compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis, J. Eur. Acad. Dermatol. Venereol20 (2006) 20–39; https://doi.org/10.1111/j.1468-3083.2005.01343.x10.1111/j.1468-3083.2005.01343.x16405606]Search in Google Scholar
[19. P. Asawanonda and Y. Nateetongrungsak, Methotrexate plus narrowband UVB phototherapy versus narowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study, J. Am. Acad. Dermatol.54 (2006) 1013–1018; https://doi.org/10.1016/j.jaad.2006.01.00410.1016/j.jaad.2006.01.00416713455]Search in Google Scholar
[20. A. Tanew, A. Guggenbichler, H. Honigsmann, J. M. Geiger and P. Fritsch, Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study, J. Am. Acad. Dermatol.25 (1991) 682–684.10.1016/0190-9622(91)70253-X]Search in Google Scholar
[21. M. Kaštelan, N. Puizina Ivić, R. Čeović, Z. Jukić, V. Bulat, E. Simonić, L. Prpić Massari, I. Brajac and G. Krnjević Pezić, Guidelines for the diagnosis and treatment of psoriasis, Liječ. Vjesn.135 (2013) 195–200.]Search in Google Scholar
[22. A. Nast, L. Amelunxen, M. Augustin, W-H. Boehncke, C. Dressler, M. Gaskins, P. Harle, B. Hoffstadt, J. Klauss, J. Koza, U. Mrowietz, H-M. Ockenfels, S. Philipp, K. Reich, T. Rosenbach, B. Rzany, M. Schlager, G. Schmid-Ott, M. Sebastian, R. Von Kiedrowski and T. Weberschock, S3 Guideline for the treatment of psoriasis vulgaris, update-short version part 1-systemic treatment, JDDG16 (2018) 645–669; https://doi.org/10.1111/ddg.1351610.1111/ddg.1351629750443]Search in Google Scholar
[23. A. Nast, P. I. Spuls, G. Van der Kraaij, P. Gisondi, C. Paul, A. D. Ormerod, P. Saiag, C. H. Smith, E. Dauden, E. M. de Jong, E. Feist, R. Jobling, M. Maccarone, U. Mrowietz, K. A. Papp, K. Reich, S. Rosumeck, T. Talme, H. B. Thio, P. van der Kerkhof, R. N. Werner and C. Dressler, European S3-Guideline on the systemic treatment of psoriasis vulgaris-update apremilast and secukinumab-EDF in cooperation with EADV and IPC, J. Eur. Acad. Dermatol. Venereol.31 (2017) 1951–1963; https://doi.org/10.1111/jdv.1445410.1111/jdv.1445428895202]Search in Google Scholar
[24. S. K. Mahil, F. Capon and J. N. Barker, Update on psoriasis immunopathogenesis and targeted immunotheapy, Semin Immunpathol.38 (2016) 11–27 https://doi.org/10.1007/s00281-015-0539-810.1007/s00281-015-0539-8470657926573299]Search in Google Scholar
[25. P. Rich, M. Gooderham, H. Bachelez, J. Goncalves, R. M. Day, R. Chen and J. Crowley. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult to treat nail and scalp psoriasis: result of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM2), J. Am. Acad. Dermatol.74 (2016) 134–142; https://doi.org/10.1016/j.jaad.2015.09.00110.1016/j.jaad.2015.09.00126549249]Search in Google Scholar
[26. M. AbuHilal, S. Walsh and N. Shear, Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: A retrospective study, J. Cutan. Med. Surg.20 (2016) 313–316; https://doi.org/10.1177/120347541663132810.1177/120347541663132826848145]Search in Google Scholar
[27. L. Hsu, B. T. Snodgrass and A. W. Armstrong. Antidrug antibodies in psoriasis: a systematic review, Br. J. Dermatol.170 (2014) 261–273; https://doi.org/10.1111/bjd.1265410.1111/bjd.12654]Search in Google Scholar
[28. K. Papp, H. Bachelez, A Constanzo, P. Foley, M. Gooderham, P. Kaur, J. Narbutt, S. Philipp, L. Spelman, J. Weglowska, N. Zhang and B. Strober, Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter phase III study, J. Am. Acad. Dermatol.76 (2017) 1093–1102; https://doi.org/10.1016/j.jaad.2016.12.01410.1016/j.jaad.2016.12.014]Search in Google Scholar
[29. T. Bito, R. Nishikawa, M. Hatakeyama, A. Kikusawa, H. Kanki, H. Nagai, Y. Sarayama, T. Ikeda, H. Yoshizaki, H. Seto, A. Adachi, T. Horikawa, M. Oka and C. Nishigiri, Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis, Br. J. Dermatol.170 (2014) 922–929; https://doi.org/10.1111/bjd.12791.10.1111/bjd.12791]Search in Google Scholar
[30. K. K. Jorgensen, I. C. Olsen, G. L. Goll, M. Lorentzen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, C. Mork, J. Jahnsen and T. K. Kvien, Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non inferiority trial, Lancet389 (2017) 2304–2316 https://doi.org/10.1016/S0140-6736(17)30068-510.1016/S0140-6736(17)30068-5]Search in Google Scholar
[31. K. Reich, A. D. Burden, J. N. Eaton and N. S. Hawkins, Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials, Br. J. Dermatol.166 (2012) 179–188; https://doi.org/10.1111/j.1365-2133.2011.10583.x10.1111/j.1365-2133.2011.10583.x21910698]Search in Google Scholar
[32. C. Ryan, C. L. Leonardi, J. G. Krueger A. B. Kimball, B. E. Strober, K. B. Gordon, R. G. Langley, J. A. de Lemos, Y. Daud, D. Blankenship, S. Kazi, D. H. Kaplan, V. E. Friedewald and A. Menter, Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials, JAMA306 (2011) 864–871; https://doi.org/10.1001/jama.2011.121110.1001/jama.2011.121121862748]Search in Google Scholar
[33. K. A. Papp, C. E. Griffiths, K. Gordon, M. Lebwohl, P. O. Szapary, Y. Wasfi, D. Chan, M. C. Hsu, V. Ho, P. D. Ghislain, B. Strober, K. Reich and PHOENIX 1 Investigators, PHOENIX 2 Investigators, ACCEPT Investigators, Long-term safety of ustekinumab in patients with moderate to severe psoriasis: final results from 5 years of follow-up, Br. J. Dermatol.168 (2013) 844–854; https://doi.org/10.1111/bjd.1221410.1111/bjd.1221423301632]Search in Google Scholar
[34. A. Blauvelt, Safety of secukinumab in the treatment of psoriasis, Expert Opin. Drug Saf.15 (2016) 1413–1420; https://doi.org/10.1080/14740338.2016.122192310.1080/14740338.2016.122192327545070]Search in Google Scholar
[35. K. B. Gordon, A. Blauvelt, P. Foley, M. Song, Y. Wasfi, B. Randazzo, Y. K. Shen, Y. You and C. E. M. Griffiths, Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies, Br. J. Dermatol.178 (2018) 132–139; https://doi.org/10.1111/bjd.1600810.1111/bjd.1600828940259]Search in Google Scholar
[36. K. Papp, D. Thaci, K. Reich, A. Blauwelt, E. Riedl, R. G. Langley, J. G. Krueger, A. B. Gottlieb, H. Nakagawa, E. P. Bowman, A. Mehta, Q. Li, Y. Zhou and R. Shames. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial, Br. J. Dermatol.173 (2015) 930–939. https://doi.org/10.1111/bjd.1393210.1111/bjd.1393226042589]Search in Google Scholar
[37. K. A. Papp, A. Blauvelt, M. Bukhalo, M. Gooderham, J. G. Krueger, J. P. Lacour, A. Menter, S. Philipp, H. Sofen, S. Tyring, B. R. Berner, S. Visvanathan, C. Pamulapati, N. Bennett, M. Flack, P. Scholl and S. J. Padula, Risankizumab versus Ustekinumab for moderate-to-severe plaque psoriasis, N. Eng. J. Med.376 (2017) 1551–1560; https://doi.org/10.1056/NEJMoa160701710.1056/NEJMoa160701728423301]Search in Google Scholar
[38. M. Amin, D. J. No, A. Egeberg and J. J. Wu, Choosing first-line biologic treatment for moderate-to-severe psoriasis: What does the evidence say? Am J. Clin. Dermatol.19 (2018) 1–13; https://doi.org/10.1007/s40257-017-0328-310.1007/s40257-017-0328-329080066]Search in Google Scholar
[39. K. Ronholt and L. Iversen, Old and new biological therapies for psoriasis, Int. J. Mol. Sci.18 (2017) E2297; https://doi.org/103390/ijms1811229710.3390/ijms18112297]Search in Google Scholar
[40. U. Mrowietz, Implementing treatment goals for successful long-term management of psoriasis, J. Eur. Acad. Dermatol. Venereol26 (2012) 12–20; https://doi.org/10.1111/j.1468-3083.2011.04411.x10.1111/j.1468-3083.2011.04411.x22356631]Search in Google Scholar
[41. A. Osmola-Mankowska, E. Teresiak-Mikolajczak, M. Skrzypczak-Zielinska and Z. Adamski, Genetic polymorphism in psoriasis and its meaning for the treatment efficacy in the future, Postepy Dermatol. Alergol.35 (2018) 331–337; https://doi.org/10.5114/ada.2018.7710.5114/ada.2018.77661]Search in Google Scholar